ImBRAVE 050 Study Results and Discussion Around Who is a High-Risk Patient

Author(s):

Panelists discuss findings from the IMmbrave050 trial comparing atezolizumab plus bevacizumab to active surveillance in patients with high-risk hepatocellular carcinoma patients, highlighting the significance of follow-up for those at risk of recurrence post- curative treatment.

EP: 1.Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

EP: 2.Treatment Decisions Based on BLCL Stage

EP: 3.Current Treatment in First Line – IO + TKI or IO + IO

EP: 4.Use of monotherapy (IO or TKI) or localized treatment in First Line

EP: 5.EMERALD-1 Study Results

EP: 6.Discussion and Summary

EP: 7.LEAP-012 Study Results

EP: 8.Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing

Now Viewing

EP: 9.ImBRAVE 050 Study Results and Discussion Around Who is a High-Risk Patient

EP: 10.Choosing Second-Line Therapies: Considering First Line Therapy Received

EP: 11.Discussion of CELESTIAL Trial and Second-Line Treatment in Japan

EP: 12.CELESTIAL Sub-Group Discussion

EP: 13.Discussion of RESORCE Trial

EP: 14.Real-World Treatment Data from the Phase 4 STELLAR Trial

Video content above is prompted by the following:

Dr Li: Please discuss the IMmBRAVEbrave050 trial evaluating atezolizumab +plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinomaHCC. (Yopp A, ESMO Congress 2024, LBA39).
• Please comment on:
o• the Iimportance or non-importance of follow-up for patients who are at high risk of recurrence after receiving curative-intent resection or ablation with curative intent.